Silence Therapeutics

Silence Therapeutics PLC
TypePublic (Nasdaq: SLN)
IndustryPharmaceuticals
Founded1994
HeadquartersHammersmith, London
Number of employees
120
Websitewww.silence-therapeutics.com

Silence Therapeutics (Nasdaq: SLN[1]), is a London-based pharmaceutical company formed in 1994. Since its origin, the company has been a pioneer in the design and development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.[2]

Profile

Silence Therapeutics develops medicines related to RNA interference or RNAi,[3] to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNA GOLD™ platform can be used to create siRNAs (short interfering RNAs) that target and silence disease-associated genes in the liver. Silence Therapeutic's product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases.

Partnerships

Silence Therapeutics has partnerships with other pharmaceutical companies, such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.

References

  1. ↑ "Google Finance Stock Exchange listing for Silence Therapeutics".
  2. ↑ "About us". silence-therapeutics.com. Archived from the original on 26 March 2023. Retrieved 26 June 2023.
  3. ↑ Hannon, Gregory J. (July 2002). "RNA interference". Nature. pp. 244–251. doi:10.1038/418244a. Retrieved 26 June 2023.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.